Achieving its Broad Clinical Spectrum: Budesonide through Alternative Kinetics

Campos Basit^*
*Correspondence: Campos Basit, Department of Pharmaceutical Technology, Gazi University, Ankara, Turkey, Email:

Introduction

Budesonide, a synthetic corticosteroid with potent anti-inflammatory properties, has emerged as a versatile medication with applications spanning respiratory disorders, such as asthma and COPD, to gastrointestinal conditions like IBD. Unlike traditional systemic corticosteroids, budesonide exhibits alternative pharmacokinetic characteristics that enhance its therapeutic efficacy while minimizing systemic side effects. This short communication article aims to elucidate the unique pharmacokinetics of budesonide, shedding light on how its alternative kinetics contribute to its broad clinical spectrum and favorable safety profile.

Description

Budesonide undergoes extensive first-pass metabolism in the liver, leading to a significant reduction in systemic bioavailability after oral administration. This high first-pass metabolism limits systemic exposure to budesonide, reducing the risk of systemic corticosteroid-related adverse effects such as adrenal suppression, osteoporosis, and immunosuppression. Budesonide's pharmacokinetics are characterized by site-specific delivery to target tissues, particularly in the respiratory and gastrointestinal tracts. Inhaled budesonide formulations (e.g., dry powder inhalers, metered-dose inhalers) deliver the medication directly to the lungs, exerting local anti-inflammatory effects with minimal systemic absorption. Enteric-coated budesonide formulations ensure targeted release in the distal ileum and colon, offering localized therapy for Crohn's disease and ulcerative colitis while reducing systemic exposure [1].

Budesonide has a relatively short plasma half-life, necessitating oncedaily or twice-daily dosing regimens for optimal therapeutic efficacy. The rapid clearance of budesonide from systemic circulation further contributes to its limited systemic effects compared to long-acting corticosteroids. Budesonide is widely used in the management of asthma and COPD, where its inhaled formulations (e.g., budesonide/formoterol combination inhalers) offer effective control of airway inflammation and symptoms. The localized action of inhaled budesonide minimizes the risk of systemic corticosteroid-related adverse effects, making it suitable for long-term maintenance therapy. In IBD, budesonide's targeted delivery to the gastrointestinal tract is advantageous for treating active disease and achieving mucosal healing [2].

Enteral budesonide formulations, such as budesonide MMX (multi-matrix system), are effective in inducing remission in patients with mild to moderate Crohn's disease and ulcerative colitis, particularly involving the distal ileum and colon. Budesonide nasal sprays are utilized in the management of allergic rhinitis and nasal polyps, providing local anti-inflammatory effects and symptom relief without significant systemic absorption. Topical budesonide preparations, such as creams or ointments, are occasionally used for treating inflammatory skin conditions like eczema or dermatitis, particularly in localized areas requiring corticosteroid therapy. Budesonide's alternative pharmacokinetics contribute to its favorable safety and tolerability profile compared to systemic corticosteroids [3,4].

The limited systemic exposure to budesonide minimizes the risk of adrenal suppression, metabolic disturbances, and immune suppression commonly associated with systemic corticosteroids. Targeted delivery of budesonide to specific tissues allows for effective anti-inflammatory effects at the site of action while sparing non-target organs from corticosteroid-related side effects. Budesonide's potency and site-specific delivery enable lower dosages compared to systemic corticosteroids, further reducing the risk of adverse events [5].

Conclusion

Budesonide's broad clinical spectrum and favorable safety profile stem from its unique pharmacokinetics, characterized by high first-pass metabolism, site-specific delivery, and short plasma half-life. These alternative kinetics allow for targeted therapy in respiratory conditions, IBD, allergic rhinitis, nasal polyps, and dermatological disorders, while minimizing systemic corticosteroid-related adverse effects. Understanding budesonide's pharmacokinetic properties is essential for optimizing its use across diverse therapeutic areas and ensuring optimal patient outcomes with reduced treatment-associated risks.

References

1. Toogood, J. H. and N. M. Lefcoe. "Dexamethasone aerosol for the treatment of “steroid dependent” chronic bronchial asthmatic patients." J Allergy 36 (1965): 321-332.

   Google Scholar, Crossref

2. Brown, H. Morrow, G. Storey and W. H. S. George. "Beclomethasone dipropionate: A new steroid aerosol for the treatment of allergic asthma." Br Med J 1 (1972): 585-590.

   Google Scholar, Crossref, Indexed at

3. Daley‐Yates, Peter T. "Inhaled corticosteroids: Potency, dose equivalence and therapeutic index." Br. J Clin Pharmacol 80 (2015): 372-380.

   Google Scholar, Crossref, Indexed at

4. Daley‐Yates, Peter, Noushin Brealey, Sebin Thomas and Daren Austin, et al. "Therapeutic index of inhaled corticosteroids in asthma: A dose–response comparison on airway hyperresponsiveness and adrenal axis suppression." Br J Clin Pharmacol 87 (2021): 483-493.

   Google Scholar, Crossref, Indexed at

5. Pavord, Ian D., Mark Holliday, Helen K. Reddel and Irene Braithwaite, et al. "Predictive value of blood eosinophils and exhaled nitric oxide in adults with mild asthma: A prespecified subgroup analysis of an open-label, parallel-group, randomised controlled trial." Lancet Respir Med 8 (2020): 671-680.

   Google Scholar, Crossref, Indexed at